Nifty 50
- Adani Enterprises₹3,16957.00 (1.83%)
- Hindalco Industries₹1,024-29.00 (-2.75%)
- Kotak Mahindra Bank₹424.207.50 (1.80%)
- HDFC Bank₹711-16.20 (-2.23%)
- Adani Ports₹1,71422.50 (1.33%)
- Mahindra & Mahindra₹3,330-68.20 (-2.01%)
- Cipla₹1,42017.30 (1.23%)
- Shriram Finance₹1,101-16.50 (-1.48%)
- Bharat Electronics₹4114.10 (1.01%)
- HCL Technologies₹1,282-16.50 (-1.27%)
- Tata Motors PV₹3162.90 (0.93%)
- Grasim Industries₹3,258-41.90 (-1.27%)
- ICICI Bank₹1,44313.00 (0.91%)
- Bharti Airtel₹1,878.30-23.80 (-1.25%)
- Tech Mahindra₹1,58514.00 (0.89%)
- Reliance Industries₹1,282.20-15.80 (-1.22%)
- Eicher Motors₹8,10065.00 (0.81%)
- Jio Financial ₹238.10-2.90 (-1.20%)
- Titan Company₹5,139.3039.30 (0.77%)
- InterGlobe Aviation₹5,189-61.50 (-1.17%)
- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Margin Pledge Calculator
- Markets
Stocks
F&O
Mutual Funds
- More
Aptus Pharma IPO
₹1,30,000/2000 shares
Minimum Investment
IPO Details
23 Sep 25
25 Sep 25
₹1,30,000
2000
₹65 to ₹70
BSE
₹13.02 Cr
30 Sep 25
Open Free Demat Account
Open Free Demat Account
Aptus Pharma IPO Timeline
Bidding Start
23 Sep 25
Bidding Ends
25 Sep 25
Allotment Finalisation
26 Sep 25
Refund Initiation
29 Sep 25
Demat Transfer
29 Sep 25
Listing
30 Sep 25
Aptus Pharma Limited
Aptus Pharma Limited, incorporated in 2010, is engaged in marketing and distribution of finished pharmaceutical formulations. The company manufactures and distributes over 194 formulations across more than eleven therapeutic segments including acute therapies, chronic care, wellness, nutraceuticals, and exports through its Aptus Global division. Its products serve antacids, pain management, anti-inflammatories, antibiotics, cardiology, neuropsychiatry, dental, injectables, syrups, and sachets. The company operates from Ahmedabad with a warehouse of 15,732 sq. ft., 125 distributors, and a field sales team of 54 employees, supporting 70 total staff.
Aptus Pharma Limited IPO Overview
The Aptus Pharma IPO is a book-building issue of ₹13.02 crore, consisting entirely of a fresh issue of 0.19 crore shares. The IPO opens for subscription on 23 September 2025 and closes on 25 September 2025, with allotment expected to be finalized on 26 September 2025. The shares will be listed on BSE SME, with a tentative listing date of 30 September 2025. The price band is set at ₹65 to ₹70 per share, and the lot size is 2,000 shares. Retail investors must invest a minimum of ₹2,80,000 for 4,000 shares, while HNI investors must subscribe to a minimum of 3 lots (6,000 shares), amounting to ₹4,20,000. Interactive Financial Services Ltd. is the book running lead manager, Bigshare Services Pvt. Ltd. is the registrar, and Market-Hub Stock Broking Pvt. Ltd. is the market maker.
Aptus Pharma Limited IPO Details
| Particulars | Details |
| IPO Date | 23 September 2025 to 25 September 2025 |
| Listing Date | 30 September 2025 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹65 to ₹70 per share |
| Lot Size | 2,000 Shares |
| Total Issue Size | 18,60,000 shares (aggregating up to ₹13.02 Cr) |
| Fresh Issue | 18,60,000 shares (aggregating up to ₹13.02 Cr) |
| Offer for Sale | NA |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 50,00,000 shares |
| Share Holding Post Issue | 68,60,000 shares |
| Market Maker Portion | 94,000 shares |
Aptus Pharma Limited IPO Reservation
| Investor Category | Shares Offered |
| Market Maker | 94,000 (5.05%) |
| QIB | 8,80,000 (47.31%) |
| NII (HNI) | 2,66,000 (14.30%) |
| Retail | 6,20,000 (33.33%) |
| Total | 18,60,000 (100%) |
Aptus Pharma Limited IPO Lot Size
| Application | Lots | Shares | Amount |
| Retail (Min) | 2 | 4,000 | ₹2,80,000 |
| Retail (Max) | 2 | 4,000 | ₹2,80,000 |
| S-HNI (Min) | 3 | 6,000 | ₹4,20,000 |
| S-HNI (Max) | 7 | 14,000 | ₹9,80,000 |
| B-HNI (Min) | 8 | 16,000 | ₹11,20,000 |
Aptus Pharma Limited IPO Promoter Holding
| Shareholding Status | Percentage |
| Pre-Issue | 100% |
| Post-Issue | 72.89% |
Aptus Pharma Limited IPO Valuation Overview
| KPI | Value |
| EPS (Pre IPO / Post IPO) | 6.20 / 4.52 |
| Price/Earnings (P/E) | 11.29 / 15.49 |
| Return on Net Worth (RoNW) | 44.50% |
| Return on Equity (ROE) | 44.50% |
| Return on Capital Employed (ROCE) | 45.66% |
| EBITDA Margin | 19.31% |
| Debt/Equity Ratio | 1.49 |
Objectives of the Proceeds
- Capital expenditure for office premises, furniture, and industrial racks – ₹1.63 Cr
- Working capital requirements to support operations – ₹8.00 Cr
- General corporate purposes to strengthen business – Amount not specified
Key Financials (in ₹ Crores)
| Particulars | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 21.92 | 10.03 | 6.22 |
| Total Income | 24.64 | 17.88 | 13.90 |
| Profit After Tax | 3.10 | 0.80 | 0.19 |
| Reserves and Surplus | 1.97 | 1.47 | 0.67 |
| Total Borrowing | 10.36 | 5.31 | 2.21 |
SWOT Analysis of Aptus Pharma IPO
Strength and Opportunities
- Diversified product portfolio across multiple therapeutic segments
- Extensive distribution network with 125 direct and sub-distributors
- Strategic manufacturing alliances across Gujarat, Uttarakhand, and Himachal Pradesh
- Competitive and cost-effective pricing strategy
- Experienced management team driving operational and strategic growth
Risks and Threats
- High debt-to-equity ratio may increase financial risk
- Dependence on regional manufacturing limits geographic diversification
- Intense competition in pharmaceutical formulations market
- Regulatory changes may impact operational efficiency
- Limited international presence restricts export opportunities
Explore IPO Opportunities
Explore our comprehensive IPO pages to stay updated on the latest trends and insights.
About Aptus Pharma Limited
Aptus Pharma IPO Strengths
- Offers a wide-ranging product portfolio covering multiple therapeutic segments and healthcare needs.
- Maintains a strong distribution network with extensive reach across regional and national markets.
- Has strategic manufacturing partnerships across Gujarat, Uttarakhand, and Himachal Pradesh locations.
- Implements competitive and cost-effective pricing strategies to attract diverse customer segments.
- Led by an experienced management team with strong industry knowledge and operational expertise.
Peer Comparison
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio |
| Aptus Pharma Limited | 5.32 | 5.32 | 13.93 | – | 44.50 | – |
| Peer Group | ||||||
| Zota Health Care Limited | 3.16 | 3.16 | 110.83 | 382.12 | 2.72 | 10.97 |
| Sunrest Lifescience Limited | 4.66 | 4.66 | 37.72 | 10.56 | 12.36 | 1.32 |
| Lincoln Pharmaceuticals Limited | 41.11 | 41.11 | 335.34 | 13.53 | 12.26 | 1.66 |
How to apply IPO with HDFC SKY?
Follow these simple steps to apply for an IPO through HDFC SKY. Secure your investments and explore new opportunities with ease by accessing the IPOs available on the platform.
- 1Login to your HDFC SKY Account
- 2Select Issue
- 3Enter Number of Lots and your Price.
- 4Enter UPI ID
- 5Complete Transaction on Your UPI App
FAQs On Aptus Pharma IPO
How can I apply for Aptus Pharma IPO?
What is the minimum investment for retail investors?
When is the tentative listing date for Aptus Pharma IPO?
Is this IPO a fresh issue or an offer for sale?
Invest Anytime, Anywhere
By signing up I certify terms, conditions & privacy policy